Comparison of inhaled corticosteroids: What you need to know in choosing a product

Pediatric, Allergy, Immunology, and Pulmonology

Volumn 24, Issue 3, 2011, Pages 175-179

  Raissy, Hengameh H ^a   Blake, Kathryn ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; MOMETASONE FUROATE; PLACEBO;

ARTICLE; ASTHMA; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; METERED DOSE INHALER; NEBULIZER; PARTICLE SIZE; PATIENT COMPLIANCE; PHARMACOGENETICS; POWDER INHALER; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE;

EID: 80053358358     PISSN: 2151321X     EISSN: 21513228     Source Type: Journal    
DOI: 10.1089/ped.2011.0094     Document Type: Article

References (59)

1. National Institutes of Health, National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Full Report of the Expert Panel: Guidelines for the diagnosis and management of asthma (EPR-3) 2007. Available at www.nhlbi.nih.gov/guidelines/asthma (last accessed April 28, 2011).
2. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332-336. (Pubitemid 30616699)
3. Dolovich MA, MacIntyre NR, Dhand R, et al. Consensus conference on aerosols and delivery devices. Respir Care 2000; 45:588-776.
4. Derendorf H, Nave R, Drollman A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006; 28:1042-1050. (Pubitemid 46335529)
5. Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009; 43:519-527.
6. Kelly HW. Potential adverse effects of inhaled corticosteroids. J Allergy Clin Immunol 2003; 112:469-478. (Pubitemid 37108546)
7. Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002; 165:1377-1383. (Pubitemid 34522940)
8. Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996; 42:697-705. (Pubitemid 26417610)
9. Smaldone GC, Cruz-Rivera M, Nikander K. In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension. J Aerosol Med 1998; 11:113-125. (Pubitemid 28259491)
10. Busse WW, Brazinsky S, Jacobson K, et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104:1215-1222. (Pubitemid 30004983)
11. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoralkane-134a beclomethasone is greater than that of chlorofluorcarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002; 122:510-516. (Pubitemid 35002128)
12. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127:335-371.
13. Raissy HH, Caffey LF, Marshik P, Harkins M, Kelly HW. Inspiratory flow through dry-powder inhalers (DPIs) in asthmatic children 2 to 12 years old. Pediatr Asthma Allergy Immuol 2006; 19:223-230. (Pubitemid 46147819)
14. Product information: AsmanexTwisthaler (R), (mometasone furoate inhalation powder) for oral inhalation only. Kenilworth, NJ: Schering-Plough Corporation, 2008.
15. Product information: PulmicortFlexhaler (R), (budesonide inhalation powder) for oral inhalation. Wilmington, DE: AstraZeneca LP, 2008.
16. Gershman NH, Wong HH, Liu JT, Fahy JV. Low-and high-dose fluticasone propionate in asthma; effects during and after treatment. Eur Respir J 2000; 15:11-18. (Pubitemid 30068929)
17. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998; 132:976-982. (Pubitemid 28280409)
18. OConnor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001; 86: 397-404. (Pubitemid 32332318)
19. Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109:e92.
20. Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999; 93:603-612. (Pubitemid 29476249)
21. Mehta V, Stokes JR, Berro A, et al. Time-dependent effects of inhaled corticosteroids on lung function, bronchial hyperresponsiveness, and airway inflammation in asthma. Ann Allergy Asthma Immunol 2009; 103:31-37.
22. Martin RJ, Szefler SJ, King TS, et al. The predicting response to inhaled corticosteroid efficacy (PRICE) trial. J Allergy Clin Immunol 2007; 119:73-80. (Pubitemid 46037824)
23. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115:233-242. (Pubitemid 40215084)
24. Knuffman JE, Sorkness CA, Lemanske RF, Jr., et al. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol 2009; 123:411-416.
25. Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410-418. (Pubitemid 34234189)
26. Hofstra WB, Neijens HJ, Duiverman EJ, et al. Dose-responses over time to inhaled fluticasone propionate treatment of exerciseand methacholine-induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29:415-423. (Pubitemid 30346466)
27. Petersen R, Agertoft L, Pedersen S. Treatment of exerciseinduced asthma with beclomethasone dipropionate in children with asthma. Eur Respir J 2004; 24:932-937. (Pubitemid 39642281)
28. Murray CS, Woodcock A, Langley SJ, et al. Secondary prevention of asthma by the use of inhaled fluticasone propionate in wheezy infants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754-762. (Pubitemid 44294820)
29. Busse WW, Pedersen S, Pauwels RA, et al. The iInhaledsteroid treatment as regular therapy in early asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167-1174.
30. OByrne PM, Pedersen S, Busse WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006; 129:1478-1485. (Pubitemid 43894975)
31. Covar RA, Spahn JD, Murphy JR, et al. Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med 2004; 170:234-241. (Pubitemid 38971407)
32. Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 2002; 57:226-230. (Pubitemid 34214408)
33. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178:682-687.
34. Sutherland ER, Goleva E, Jackson LP, et al. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med 2010; 181:699-704.
35. Tantisira KG, Stephen L, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13:1353-1359. (Pubitemid 38961642)
36. Tantisira KG, Lazarusa R, Litonjua AA, et al. Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogen Genomics 2008; 18:733-737.
37. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009; 180:817-822.
38. Lim KG, Rank MA, Li JT, et al. How well does patient self-report predict asthma medication possession? Implications for medication reconciliation and adherence assessment. J Asthma 2010; 47:878-882.
39. OByrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164:1392-1397. (Pubitemid 33124016)
40. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. N Engl J Med 1997; 337:1405-1411.
41. Szefler SJ, Eigen H. Budesonide inhalation suspension: a nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol 2002; 109:730-742. (Pubitemid 34327207)
42. Masoli M, Weatherall M, Holt S, et al. Systematic review of the dose-response relation of inhaled fluticasone propionate. Arch Dis Child 2004; 89:902-907.
43. Zhang L, Axelsson I, Chung M, Lau J. Dose response of inhaled corticosteroids in children with persistent asthma: a systematic review. Pediatrics 2011; 127:129-138.
44. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001; 61:1325-1350. (Pubitemid 32744413)
45. Masoli M, Holt S, Weatherall M, Beasley R. Dose-response relationship of inhaled budesonide in adult asthma: a metaanalysis. Eur Respir J 2004; 23:552-558. (Pubitemid 38455996)
46. Adams N, Bestall JM, Lasserson TJ, Jones PW. Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2005; 2:CD002310.
47. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Palmqvist M, et al. Can guideline-defined asthma control be achieved? Am J Respir Crit Care Med 2004; 170:836-844.
48. Kelly HW. Alveolar nitric oxide concentration, small airways inflammation, and targeted asthma therapy: are we there yet? J Allergy Clin Immunol 2010; 126:736-737.
49. Amirav I, Newhouse MT, Minocchieri S, Castro-Rodriguez JA, Schu epp KG. Factors that affect the efficacy of inhaled corticosteroids for infants and young children. J Allergy Clin Immunol 2010; 125:1206-1211.
50. Tunon-de-Lara J-M, Laurent F, Girard V, et al. Air trapping in mild and moderate asthma: effect of inhaled corticosteroids. J Allergy Clin Immunol 2007; 119:583-590. (Pubitemid 46335813)
51. Robroeks CMHHT, van de Kant KD, van Vliet D, et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasonevs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Ann Allergy Asthma Immunol 2008; 100:601-607. (Pubitemid 351829861)
52. Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomized, double-blind, placebo-controlled trial. Lancet 2011; 377:650-657.
53. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006; 148:377-383.
54. Pedersen S, Garcia Garcia ML, Manjra AI, Theron I, Engelsta tter R. A comparative study of inhaled ciclesonide 160 mg/day and fluticasonepropionate 176 mg/day in children with asthma. Pediatr Pulmonol 2006; 41:954-961. (Pubitemid 44534813)
55. Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985-1997.
56. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000; 106:E8.
57. Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf 2006; 29:599-612. (Pubitemid 44175030)
58. Milgrom H. Mometasone furoate in children with mild to moderate persistent asthma a review of the evidence. Pediatr Drugs 2010; 12:213.
59. Skoner DP, Maspero J, Banerji D; and the Ciclesonide Pediatric Growth Study Group. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008; 121:e1-e14.